Pentalafen® + Heliance Solution
Newly Diagnosed Glioblastoma (GBM)
Phase 2/3 (Pivotal planning)Active
Key Facts
Indication
Newly Diagnosed Glioblastoma (GBM)
Phase
Phase 2/3 (Pivotal planning)
Status
Active
Company
About Hemerion
Hemerion Therapeutics is pioneering a disruptive photonic-based therapy for glioblastoma, a devastating brain cancer with no cure. Its platform combines a proprietary drug, Pentalafen®, with a laser-based device (Heliance Solution) to target and kill cancer cells during surgical resection. The company has generated promising early clinical data, received positive regulatory feedback from the FDA and European agencies, and is preparing for a pivotal clinical trial. Hemerion's approach aims to significantly improve survival and quality of life by seamlessly integrating into the current surgical workflow.
View full company profile